Most Popular Stories
- Walgreens plans 100 more retail clinics by mid-2009
- Disruptive doctor behavior causes mistakes, intimidates workers
- AHA survey: Negative profit margins for hospitals
- DOD, VA move to SOA architecture to build interoperable systems
- HHS: 60 percent of DME companies banned by Medicare may keep billing
- Cleveland Clinic lists potential conflicts of interest online
Poll
Featured Jobs
-
New Hampshire Physical Therapist JK1021maNET
StaffPointe, LLC - northern , NH -
Washington Nurse Practitioner
StaffPointe, LLC - Tacoma/Olympia , WA -
Colorado NP or PA
StaffPointe, LLC - southeast , CO -
Virginia Nurse Mgr Emergency Dept
StaffPointe, LLC - Fredericksburg , VA -
Texas Hospitalist
StaffPointe, LLC - south , TX
Events
- Avaya Patient Payment Recovery Webinar
Thursday, December 11, 2008 1-2pm
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
- Emerging markets series: Benchmarking key countries Brazil, Russia, India, China and Turkey
Popular Topics
Despite safety issues, Vioxx still in demand
August 7, 2007 — 6:59am ET
For every regulatory action, it seems that there must be a backlash. This time, it's a move by consumers to bring back the controversial drug, Vioxx. Patients who once depended on the drug for arthritis relief are still lobbying Merck to get the drug back on the market--despite the documented risk of heart attacks, strokes, even death. Consumer advocates say it might be a case of rose-colored hindsight; patients convinced only Vioxx can help them may simply have exaggerated memories of the drug's effects.
To learn more about this story:
- read this piece from FiercePharma
Related Articles:
Vioxx defense dealt a blow by new study results. Report
Up to 100,000 Vioxx claims expected. Report
Merck faces long road in Vioxx battle. Report
Be the first to comment
Related Stories
- Merck agrees to pay$650M+ to settle suits
- SPOTLIGHT: Hung jury forces mistrial in Vioxx suit
- ALSO NOTED: TN Medicaid to test e-prescribing program; NIH alerts patients of stolen personal information; and much more...
- Reports suggest that Merck downplayed Vioxx risks
- Studies show problems with four big-name drugs
- Fourth Vioxx trial begins
- Metric: Brand drug prices surge ahead of inflation rate
- Justice Department recovers $1.12 billion from fraud
- FL sues Merck over Vioxx marketing
- Merck agrees to $58M settlement on Vioxx ads
Comments
Post new comment
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |





